Prevention and treatment of the most important sequelae in patients who have suffered from COVID-19 pneumonia.

The sequelae caused by COVID-19 pneumonia (e.g. pulmonary fibrosis, which causes breathing difficulties) currently have few therapeutic options and their monitoring and prognosis is hampered by the absence of valid biological markers (substances used as indicators of a biological state that help predict the likelihood of a patient developing sequelae). The proposal aims on the one hand to establish the validity of one or more biomarkers and on the other hand to evaluate the efficacy of a drug, the Metformin, widely used for other clinical indications and with a safe and well known therapeutic use to treat sequelae such as pulmonary fibrosis.

Principal Investigator: Santiago Lamas (CBMSO)  

We use cookies on this site to improve your user experience. More info. ACEPTAR

Aviso de cookies